Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma

Herrlinger, Ulrich, Schabet, Martin, Brugger, Wolfram, Kortmann, Rolf‐Dieter, Küker, Wilhelm, Deckert, Martina, Engel, Corinna, Schmeck‐Lindenau, Hans‐Jürgen, Mergenthaler, Hans‐Günther, Krauseneck, Peter, Benöhr, Christian, Meisner, Christoph, Wiestler, Otmar D., Dichgans, Johannes, Kanz, Lothar, Bamberg, Michael, Weller, Michael·2002·Annals of Neurology

Abstract

The prospective multicenter NOA‐03 trial, conducted by the Neuro‐Oncology Working Group (NOA) of the German Cancer Society, was initiated to define the feasibility and efficacy of single‐agent high‐dose methotrexate therapy without concomitant radiotherapy in immunocompetent patients with primary central nervous system lymphoma. Thirty‐seven patients (median age, 60 years) received 179 biweekly courses of 8g/m 2 methotrexate. Response was assessed after 3 and 6 courses. We had planned to enter 105 patients into the trial. Since fewer than the projected 18 of 37 patients achieved a complete response after an intermediate analysis, the trial was closed. In intention‐to‐treat analysis, 11 of 37 patients (29.7%) achieved complete response, whereas 14 of 37 patients (37.8%) were found to have progressive disease. The median relapse‐free survival among complete response patients was 13.7 months. Multivariate logistic regression analysis revealed that corticosteroid application during the first methotrexate course was associated with complete response. The regimen was well tolerated, but, unlike previously reported results, the activity of high‐dose methotrexate was only moderate.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.10102

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 180

Metadata

Authors
Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck‐Lindenau, H., Mergenthaler, H., Krauseneck, P., Benöhr, C., Meisner, C., Wiestler, O. D., Dichgans, J., Kanz, L., Bamberg, M., & Weller, M.
Venue
Annals of Neurology
Publisher
Wiley
Published
2002-01-31
Volume
51
Issue
2
Pages
247-252
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1987104278
Cited by
180
References
1
FWCI
10.25
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma. https://app.cochat.ai/papers/10.1002/ana.10102
The paper
Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R., Küker, W., Deckert, M., Engel, C., Schmeck‐Lindenau, H., Mergenthaler, H., Krauseneck, P., Benöhr, C., Meisner, C., Wiestler, O. D., Dichgans, J., Kanz, L., Bamberg, M., & Weller, M. (2002). German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma. Annals of Neurology. https://doi.org/10.1002/ana.10102

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.